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Background: The analysis of cellular networks and pathways involved in oncogenesis has increased our knowledge
about the pathogenic mechanisms that underlie tumour biology and has unmasked new molecular targets that
may lead to the design of better anti-cancer therapies. Recently, using a high resolution loss of heterozygosity
(LOH) analysis, we identified a number of potential tumour suppressor genes (TSGs) within common LOH regions
across cases suffering from two of the most common forms of Non-Hodgkin’s lymphoma (NHL), Follicular Lymphoma
(FL) and Diffuse Large B-cell Lymphoma (DLBCL). From these studies LOH of the protein tyrosine phosphatase receptor
type J (PTPRJ) gene was identified as a common event in the lymphomagenesis of these B-cell lymphomas. The present
study aimed to determine the cellular pathways affected by the inactivation of these TSGs including PTPRJ in FL and
DLBCL tumourigenesis.
Results: Pathway analytical approaches identified that candidate TSGs located within common LOH regions participate
within cellular pathways, which may play a crucial role in FL and DLBCL lymphomagenesis (i.e., metabolic pathways).
These analyses also identified genes within the interactome of PTPRJ (i.e. PTPN11 and B2M) that when inactivated in
NHL may play an important role in tumourigenesis. We also detected genes that are differentially expressed in cases
with and without LOH of PTPRJ, such as NFATC3 (nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 3). Moreover, upregulation of the VEGF, MAPK and ERBB signalling pathways was also observed in
NHL cases with LOH of PTPRJ, indicating that LOH-driving events causing inactivation of PTPRJ, apart from possibly
inducing a constitutive activation of these pathways by reduction or abrogation of its dephosphorylation activity, may
also induce upregulation of these pathways when inactivated. This finding implicates these pathways in the lympho-
magenesis and progression of FL and DLBCL.
Conclusions: The evidence obtained in this research supports findings suggesting that FL and DLBCL share common
pathogenic mechanisms. Also, it indicates that PTPRJ can play a crucial role in the pathogenesis of these B-cell tumours
and suggests that activation of PTPRJ might be an interesting novel chemotherapeutic target for the treatment of
these B-cell tumours.
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The identification of altered pathways in tumour cells
has provided a more holistic understanding of the patho-
genic mechanisms that underlie the genesis, progression
and chemoresponse of cancer. As a consequence, mal-
function of a gene or a group of genes must be analysed as
part of a complex network of components that are highly
related to each other. However, this analysis is limited by
factors such as the lack of analytic tools to convert and in-
tegrate, in a feasible and reliable manner, large amounts of
data derived from different high-throughput genomic ap-
proaches into outputs with more biological meaning.
Non-Hodgkin’s lymphoma (NHL) represents a highly
biological and clinical heterogeneous group of blood can-
cers [1,2]. Two of the most common NHL subtypes are
Diffuse Large B-cell Lymphoma (DLBCL), an aggressive
lymphoma, and Follicular lymphoma (FL), a slow-growing
type of lymphoma, which account for around 50% of NHL
cases [1,3]. The poor treatment outcomes obtained be-
tween 20-40% of cases with these NHL lymphomas has
prompted studies aimed at the discovery of genes and
pathways that could act as novel targets for a therapy that
increase the survival rates of patients suffering from NHL
[4-6]. However, the high genetic variability observed within
NHL subtypes, has limited the understanding of the path-
ology of these NHL subtypes, as well as the discovery of
new molecular targets for therapeutic development.
In a previous study, the integration of copy number
(CNV) and gene expression profiling (GEP) data from
DLBCL and FL cases, allowed us to identify common
and disease-specific genetic alterations targeting known
oncogenic pathways, such as the mitogen activated pro-
tein kinase (MAPK) and apoptosis signalling pathways,
unmasking common pathogenic mechanisms under-
lying the malignant phenotype of these biologically and
genetically distinct NHL subtypes [7]. Likewise, in a recent
study, using a high resolution loss of heterozygosity (LOH)
analysis in FLs and DLBCLs, we also identified candidate
tumour suppressor genes (TSGs) within common LOH re-
gions across these NHL subtypes and implicated them in
the lymphomagenesis of these B-cell lymphomas [8]. In
this study, we have performed pathway analysis of these
candidate TSGs, in order to identify common cellular
networks that might be altered by the inactivation of
one or more TSGs in the lymphomagenesis of these
B-cell lymphomas.
As part of our recent LOH studies, we also implicated
PTPRJ (protein tyrosine phosphatase receptor type J) as
a novel TSG in the tumourigenesis of FL and DLBCL,
with LOH of PTPRJ identified as a common event in FL
and DLBCL. LOH of PTPRJ was also confirmed by a
decrease of heterozygosity of a microsatellite targeting
PTPRJ loci in these NHL cases. In addition, FL cases
with LOH exhibited a significant downregulation ofPTPRJ [8]. Several lines of evidence support the tumour
suppressive role of PTPRJ, as this protein tyrosine phos-
phatase has been implicated in the oncogenesis of breast,
lung, colorectal, thyroid and meningioma cancers [9-12].
Furthermore, PTPRJ regulates signalling pathways in-
volved in cell growth, proliferation and angiogenesis,
such as MAPK (ERK1/2), PLCG1, PI3K (p85), FLT3,
B-cell receptor (BCR), PDGFRB and VEGFR2 signal-
ling [13-19]. Nonetheless, the natural ligands of PTPRJ,
Syndecan-2 (SDC2), a transmembrane heparan sulfate
proteoglycan, and Thrombospondin-1 (THBS1), a homo-
trimeric glycoprotein, have been identified to induce cell
adhesion and inhibit cell growth and angiogenesis, re-
spectively [20,21]. This anti-tumour activity of PTPRJ has
also been demonstrated in In vitro experiments, using
agonist peptides of PTPRJ and the oncogenic silencing of
PTPRJ expression by microRNA-328 expression [22-24].
Since the role of PTPRJ in normal and malignant
B-cell differentiation is poorly understood, we used path-
way and genomic analyses to identify cellular pathways that
may be altered by the inactivation of PTPRJ in order to pro-
vide a better understanding of the role of PTPRJ in the lym-
phomagenesis of FL and DLBCL. These analyses identified
metabolic pathways as one of the most enriched and af-
fected pathways resulting from the inactivation of candidate
TSGs, indicating that these cellular pathways might play an
important role in FL and DLBCL tumourigenesis. Add-
itionally, inactivation of PTPRJ was shown to affect the
expression of a number of genes and pathways that are reg-
ulated by PTPRJ through protein-protein interactions.
Results
Candidate tumour suppressor genes (TSGs) targeted by
LOH events participate within common cellular networks
that may orchestrate NHL lymphomagenesis
In order to determine whether the candidate tumour
suppressor genes (TSGs) located within common LOH re-
gions across DLBCL and FL cases interact and participate
within common cellular networks, a global interactome of
a total of 262 genes affected by LOH events [8], was cre-
ated using the VisANT (v. 4.06) platform (Figure 1). As a
result of this analysis, the METABOLIC pathway (KEGG
hsa-01100) was identified as the most enriched pathway
by these candidate TSGs. This approach also revealed a
high level of interaction amongst these candidate TSGs
targeted by LOH events, indicating that NHL tumourigen-
esis might be orchestrated by the possible inactivation of
these candidate TSGs, which could lead to the constitutive
activation of oncogenic pathways. In this context, it is
important to highlight that the genes MAPK6 (mitogen-
activated protein kinase 6), PTPN11 (protein tyrosine
phosphatase, non-receptor type 11) and ANXA7 (annexin
A7) showed the highest number of links with other genes
(170, 122 and 106 respectively). The high number of
Figure 1 Global interactome of genes commonly affected by LOH across NHL patients. An initial list containing 262 genes was used;
however, only those with more than one interaction are shown. A total of 1270 nodes belonging to 68 pathways were mapped, which
indicates the high level of interaction among the genes targeted by LOH-driving events in NHL tumours. The genes with labels correspond to
the questioned LOH genes.
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activation of these genes may cause a major deregulation
of patwhays by altering the function of a high number of
genes. Thus, these genes are shown as the most interest-
ing candidate TSGs in NHL lymphomagenesis.
In addition to the global interactome study, a gene set
enrichment analysis (GSEA) was performed to classify the
262 candidate TSGs targeted by LOH events, thenceforth
also referred in this study as LOH genes, into curated gene
families and also to determine the pathways that are
mostly enriched with these genes. This approach cate-
gorized these LOH genes into gene families (Additional
file 1). For instance, FASLG was classified into the cyto-
kines and growth factor family and together with PTPRJ
into the cell differentiation markers family. EP300 was
found in the translocated cancer gene, transcription
factor and tumour suppressor gene families. Addition-
ally, MAPK6, PTPN11 and NFATC3 were identified as
members of the protein kinases, oncogenes and tran-
scription factors families, respectively.
Furthermore, 215 out of 262 genes within LOH re-
gions were identified and contrasted with collections
from the molecular signature database (MsigDB, v3.1).Several cellular pathways were identified to be enriched
with genes located within LOH regions (Table 1). The
most enriched pathways for LOH genes were the,
KEGG_ARGININE_AND_PROLINE METABOLISM,
REACTOME_DOUBLE STRAND_BREAK_REPAIR and
MICROTUBULE_ASSOCIATED_COMPLEX GO (gene
ontology) gene sets. Interestingly, the TSGs TP53BP1 and
B2M were identified as members of the REACTOME_
DOUBLE_STRAND_BREAK_REPAIR and BIOCARTA_
CTL PATHWAY pathways, respectively.
Significant enrichment of LOH genes was also ob-
served in a collection of gene sets with chemical and
genetic alterations (CGP), indicating that these candidate
TSGs have been previously implicated in multiple forms
of cancer (Additional file 2). In this collection, MARSON_
BOUND_BY_FOXP3_STIMULATED, DIAZ_CHRONIC
MEYLOGENOUS_LEUKEMIA_UP and GRAESSMANN_
RESPONSE_TO_MC AND _DOXORUBICIN_UP were
the one of most significant gene sets. To highlight,
PTPRJ was included in the ROYLANCE_BREAST_
CANCER_16Q_COPY_NUMBER_DN and TP53BP1 was
listed in the PUJANA_BREAST_CANCER_LIT_INT_
NETWORK gene sets.
Table 1 List of cellular pathways enriched with genes within LOH regions
Gene set name K Description k k/K* P value
KEGG_Arginine_and_proline_metabolism 54 Arginine and proline metabolism 6 0.1111 4.84 × 10−4
Reactome_double_strand_break_repair 24 Genes involved in Double-Strand Break Repair 3 0.125 9.73 × 10−3
Microtubule_associated_complex 47 Genes annotated by the GO term GO:0005875.
Any multimeric complex connected to a microtubule.
4 0.0851 1.13 × 10−2
PID_S1P_S1P3_pathway 29 S1P3 pathway 3 0.1034 1.64 × 10−2
Reactome_unwinding_of_DNA 11 Genes involved in Unwinding of DNA 2 0.1818 1.71 × 10−2
Biocarta_FAS_pathway 30 FAS signaling pathway (CD95) 3 0.1 1.80 × 10−2
Reactome_downregulation_of_ERBB2_ERBB3_SIGNALING 12 Genes involved in Downregulation of
ERBB2:ERBB3 signaling
2 0.1667 2.03 × 10−2
KEGG_Non_homologous_end_joining 14 Non-homologous end-joining 2 0.1429 2.73 × 10−2
PID_IL5_pathway 14 IL5-mediated signaling events 2 0.1429 2.73 × 10−2
Protein_kinase_binding 62 Genes annotated by the GO term GO:0019901.
Interacting selectively with a protein kinase, any
enzyme that catalyzes the transfer of a phosphate
group, usually from ATP, to a protein substrate.
4 0.0645 2.84 × 10−2
Biocarta_CTL_pathway 15 CTL mediated immune response against target cells 2 0.1333 3.11 × 10−2
MIPS_Emerin_complex_24 15 Emerin complex 24 2 0.1333 3.11 × 10−2
Cytoskeletal_part 235 Genes annotated by the GO term GO:0044430.
Any constituent part of the cytoskeleton.
9 0.0383 3.23 × 10−2
KEGG_Cell_cycle 128 Cell cycle 6 0.0469 3.28 × 10−2
Myosin_complex 16 Genes annotated by the GO term GO:0016459.
A protein complex that functions as a molecular
motor; uses the energy of ATP hydrolysis to
move actin filaments.
2 0.125 3.51 × 10−2
PID_DNAPK_pathway 16 DNA-PK pathway in nonhomologous end joining 2 0.125 3.51 × 10−2
Kinase_binding 70 Genes annotated by the GO term GO:0019900.
Interacting selectively with a kinase.
4 0.0571 4.17 × 10−2
Biocarta_MCM_pathway 18 CDK Regulation of DNA Replication 2 0.1111 4.36 × 10−2
Lipoprotein_binding 18 Genes annotated by the GO term GO:0008034. 2 0.1111 4.36 × 10−2
*k/K is the ratio between the number of genes in overlap (k) and the number of genes in gene set (K). This table combines the results from the collection of gene
sets from canonical pathways, BioCarta, KEGG, Reactome, and GO (gene ontology) gene sets.
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PTPN11 (protein tyrosine phosphatase, non-receptor
type 11), a candidate TSG also found to be targeted by
common LOH events in NHL
In a recent study, the protein tyrosine phosphatase recep-
tor type J (PTPRJ) gene was implicated as a novel TSG in
the lymphomagenesis of DLBCL and FL [8]. In this previ-
ous study, using publically available gene expression pro-
filing data from our cohort of NHL cases and subsequent
validation by qualitative PCR (qPCR), a significant down-
regulation of PTPRJ expression in FL cases with LOH,
indicating that the LOH-driving events targeting PTPRJ
might have an effect on mechanisms regulating the
expression of PTPRJ [7,8]. This significant reduction in
PTPRJ transcript abundance may result in haploinsuffi-
ciency of this TSG and thus, play a crucial role in the FL
and DLBCL tumourigenesis. Based on this, we performed
in silico pathway and gene expression analyses in order to
provide more information about the unclear role andfunction of PTPRJ in normal and malignant B-cell devel-
opment and to understand the effect of LOH of PTPRJ in
the lymphomagenesis of FL and DLBCL from a more cel-
lular perspective.
Initially, we studied the interactome of PTPRJ to deter-
mine whether candidate TSGs, affected by LOH events,
interact directly or indirectly with PTPRJ and play a role
together with PTPRJ, within common cellular networks.
The analysis of the gene-gene interactions of PTPRJ
revealed that none of the 41 genes, which are known to
interact with PTPRJ, were previously identified among
the genes located within the common LOH regions across
FLs and DLBCLs (Figure 2) [8]. However, 22 genes that
interact indirectly (one level) with PTPRJ were found to
be commonly inactivated in NHL cases. Among these can-
didate TSGs, B2M (Beta-2_microglobulin) and PTPN11
(protein tyrosine phosphatase, non-receptor type 11) were
highlighted. B2M was found to interact indirectly with
PTPRJ, through the PTPRJ-GRB2-B2M interaction.
Figure 2 Interactome of PTPRJ indicates that the inactivation of PTPRJ may affect cellular networks and that these networks are not
only altered by inactivation of PTPRJ. PTPRJ gene network showing A) all the known genes that interact with PTPRJ and B) only those genes
that were also found to be inactivated in NHL cases. Two levels of interaction were used to filter the interactions. Interestingly, we found that the
gene PTPN11, which was also found inactivated in NHL cases, shares some target genes with PTPRJ; moreover, B2M has an indirect interaction
with PTPRJ (red arrows).
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was identified to share 24 interacting genes with PTPRJ.
Additionally, using previously published high resolution
LOH data, LOH of PTPN11 was identified in 74% of
NHL, 71% of FL and 76% of DLBCL cases [8].
The genes showing interaction with both PTPRJ and
PTPN11 are: MAPK3 (mitogen-activated protein kinase
3), GRB2 (growth factor receptor-bound protein 2), ERBB2
(v-erb-b2 erythroblastic leukemia viral oncogene homolog
2), MET (met proto-oncogene (hepatocyte growth factor
receptor), PDGFRB (platelet-derived growth factor recep-
tor, beta polypeptide), CTNNB1 (catenin (cadherin-associ-
ated protein), beta 1, 88 kDa), PLCG1 (phospholipase C,
gamma 1), CBL (Cas-Br-M (murine) ecotropic retroviral
transforming sequence), KIT (v-kit Hardy-Zuckerman
4 feline sarcoma viral oncogene homolog), NTRK1
(neurotrophic tyrosine kinase, receptor, type 1), KDR
(kinase insert domain receptor (a type III receptor tyro-
sine kinase)), PXN (paxillin), GAB1 (GRB2-associated
binding protein 1), LEPR (leptin receptor), EPOR (erythro-
poietin receptor), GHR (growth hormone receptor),
CXCR4 (chemokine (C-X-C motif) receptor 4), CSK (c-src
tyrosine kinase), INSR (insulin receptor), JAK2 (Janus kin-
ase 2), LCK (lymphocyte-specific protein tyrosine kinase),
GRIN2B (glutamate receptor, ionotropic, N-methyl D-
aspartate 2B), TEK (TEK tyrosine kinase, endothelial) and
TIE1 (tyrosine kinase with immunoglobulin-like and EGF-
like domains 1). Interestingly, these 24 genes were found
to significantly enrich important signalling pathways inlymphocyte biology, which suggests that a double inactiva-
tion of PTPRJ and PTPN11 might have an aberrant effect
on the function of these pathways (Table 2).
LOH of PTPRJ induces deregulation of genes and
signalling pathways in NHL tumours
We also used gene expression profiling (GEP) data from
NHL patients with known LOH status for PTPRJ [7], to
detect genes that are significantly deregulated by LOH
of PTPRJ. Using this approach, we identified differen-
tially expressed genes between cases with and without
LOH of PTPRJ. This result indicates that LOH of PTPRJ
could have an effect on the expression pattern of some
genes (Figure 3A), suggesting that some pathways might
be differentially enriched between the two categories. In
order to prove this hypothesis, a Gene Set Enrichment
Analysis (GSEA) identified some cellular pathways with
significant upregulation in cases with retention and some
others, in cases with LOH (Figure 3B and 3C). The genes
that were upregulated in the most significant gene sets are
described in Table 3. The lists of the gene sets enriched
in each LOH status (RET or LOH) are detailed in the
Additional file 3 and Additional file 4. Nonetheless, it
is important to highlight that despite all enrichment ana-
lyses exhibiting FDR values equal to 1, the results from
these gene-set enrichments, described in Figure 3 and
Table 3, were analysed based on the nominal significance
(P value lower than 0.05) instead of the FDR values, due
to the low population size, which could be driving the
Table 2 List of gene sets commonly regulated by PTPRJ and PTPN11 based on gene expression
Gene set name K k k/K* P value
KEGG_Pathways_in_cancer 328 10 0.0305 6.86 × 10−7
KEGG_Focal_adhesion 201 8 0.0398 1.70 × 10−6
KEGG_ERBB_Signaling_pathway 87 6 0.069 1.81 × 10−6
KEGG_Cytokine_cytokine_receptor_interaction 267 8 0.03 1.42 × 10−5
KEGG_Neurotrophin_signaling_pathway 126 6 0.0476 1.57 × 10−5
KEGG_Adherens_junction 75 5 0.0667 1.76 × 10−5
KEGG_Prostate_cancer 89 5 0.0562 4.06 × 10−5
KEGG_JAK_Stat_signaling_pathway 155 6 0.0387 5.11 × 10−5
KEGG_Endometrial_cancer 52 4 0.0769 7.76 × 10−5
KEGG_Non_small_cell_lung_cancer 54 4 0.0741 9.01 × 10−5
KEGG_T_Cell_receptor_signaling_pathway 108 5 0.0463 1.03 × 10−4
KEGG_Endocytosis 183 6 0.0328 1.29 × 10−4
KEGG_Chemokine_signaling_pathway 190 6 0.0316 1.59 × 10−4
KEGG_Glioma 65 4 0.0615 1.87 × 10−4
KEGG_Renal_cell_carcinoma 70 4 0.0571 2.49 × 10−4
KEGG_Thyroid_cancer 29 3 0.1034 2.81 × 10−4
KEGG_VEGF_signaling_pathway 76 4 0.0526 3.42 × 10−4
KEGG_Leukocyte_transendothelial_migration 118 4 0.0339 1.80 × 10−4
KEGG_Acute_myeloid_leukemia 60 3 0.05 2.40 × 10−3
*k/K is the ratio between the number of genes in overlap (k) and the number of genes in gene set (K).
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gene-sets that were significantly upregulated in cases with
LOH of PTPRJ.
NFATC3 is a commonly inactivated TSG in NHL cases and
is significantly upregulated in cases with LOH of PTPRJ
In order to identify genes, previously found to be inacti-
vated in our high resolution LOH study [8], and that are
differentially expressed in the context of LOH of PTPRJ,
we compared 262 candidate TSGs located within LOH
regions against the 400 genes with differential expression
between cases with retention and LOH of PTPRJ. This
approach identified only the NFATC3 (nuclear factor of
activated T-cells, cytoplasmic, calcineurin-dependent
3) gene, located at 16q22, to be commonly inactivated
and differentially expressed in NHL cases with LOH of
PTPRJ (Figure 4). Comparison of the mean fluorescence
intensity values for NFATC3 between NHL cases with re-
tention and LOH of PTPRJ revealed that NFATC3 was sig-
nificantly upregulated in cases with LOH of PTPRJ (325
vs. 375; P = 0.042). Furthermore, It is important to men-
tion that LOH of NFATC3 was found in 58% of NHL, 48%
of FL and 67% of DLBCL cases [8].
Discussion
The implementation of pathway analyses on candidate
tumour suppressor genes (TSGs) found to be targeted byloss of heterozygosity in NHL, provided a holistic perspec-
tive of the shared cellular mechanisms underlying the
lymphomagenesis of the commonest forms of NHL, FL
and DLBCL. This analytical approach unmasked the path-
ways that are mostly altered by the genetic inactivation of
TSGs potentially caused by LOH events in NHL and re-
vealed common pathogenic mechanisms between FL and
DLBCL. The analysis of candidate tumour suppressor
genes, previously identified to be located within common
LOH regions across FL and DLBCL cases [8], via inter-
actome and pathway analytical approaches, identified
the KEGG METABOLIC pathway (hsa-01100) and the
ARGININE AND PROLINE METABOLISM pathway
(hsa-00330) as the most enriched pathways in relation
to these candidate TSGs. In addition, this finding sug-
gests that the regulation of these pathways might be
commonly altered in NHL. These candidate TSGs encode
proteins (i.e., enzymes) that may directly or indirectly
(i.e., transcriptional regulators) disrupt the activity of
these pathways ,either by reduced or null expression
of these genes with tumour suppressor activity or by
the encoding of dysfunctional proteins, resulting from
the LOH-induced inactivation of these TSGs.
Disruption of metabolic pathways such as energy pro-
duction or biosynthesis of amino acids, nucleosides, etc.
are one of the hallmarks in cancer, as the malignant cells
demand a higher activity in energy metabolism and
Figure 3 Genes and pathways affected by LOH of PTPRJ. A) Heatmap of genes differentially expressed between cases with retention (RET)
and LOH calls. B) DNA polymerase (HSA03030), TP53 signaling pathway (HSA04115) and Proteasome (HSA03050) were identified as the most
enriched gene sets in cases with retention of PTPRJ. C) In cases with LOH, the gene sets VEGF signaling pathway (HSA04370), Melanoma
(HSA05218), ERBB signaling pathway (HSA04012), Calcium signaling pathway (HSA04020), FC Epsilon RI signaling pathway (HSA04664) and MAPK
signaling pathway (HSA04010) were the most enriched. Despite an FDR (false discovery rate) of 1 for all the enrichments, the results from this
gene-set enrichment analysis were analysed based on the P values instead of the FDR scores. The high FDR values obtained in this analysis may
be due to the low population size. The lists of all gene sets from this analysis are provided in Additional file 3 and Additional file 4.
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celerated proliferation and their malignant performance
[25,26]. The purpose of this metabolic reprogramming
of tumour cells is not only to increase the energy output
in these cells but it is also to maximize the biosyn-
thetic pathways of the malignant cells to turn them
into more efficient and self-sustaining organisms [25-27].
For instance, reprogramming of the glutamine-proline-
arginine metabolic circuit has been associated with cancer
and found to be regulated by TP53 and MYC, in which
proline acts as the regulatory axis of this circuit [27,28].
Therefore, the significant enrichment of candidate TSGs
in the metabolic pathways related to arginine and proline
metabolism in our samples is evidence that this repro-
gramming of energetic and biosynthetic pathways is im-
portant in NHL tumour cells. However, further functional
studies are required to corroborate the effect of LOH
events targeting these TSGs in the function of this meta-
bolic pathway and its role in the tumourigenesis of FL and
DLBCL.Using an annotated network database enriched with
protein-protein interactions and associations, we were
able to visualize the interactome of PTPRJ in relation to
candidate TSGs located within LOH regions. This ana-
lysis determined that PTPRJ does not interact directly
with any other possible LOH genes; however, this TSG
indirectly interacts with 22 possible inactivated TSGs by
LOH in NHL cases. This finding suggests that the malig-
nant phenotype of tumoural B-cells is orchestrated by an
uncontrolled activation of oncogenic signaling pathways,
which may be caused by the inactivation of the dephos-
phorylation activity of PTPRJ together with the inactiva-
tion of other TSGs that might regulate direct targets of
PTPRJ within these pathways. For instance, PTPRJ inter-
acts directly with GRB2, a pivotal protein in signal trans-
duction that activates the RAS-MAPK pathway, which is
inactivated by the dephosphorylation activity of PTPRJ.
GRB2 was also found to interact directly with B2M in
an unclear manner [29]. Interestingly, B2M was found
to be inactivated in NHLs and its inactivation has been
Table 3 List of genes enriched within the gene sets differentially expressed between cases with retention and LOH of
PTPRJ
Gene sets Genes
Upregulated in RET cases
HSA03030_DNA_Polymerase POLQ,PRIM1,POLD3,POLE3,POLK,POLE2,POLE4,POLS,REV1,POLA2,RFC5,POLD1,POLB,POLI,POLE
HSA04115_P53_Signaling_ pathway CDC2,PTEN,TNFRSF10B,CHEK1,PMAIP1,CDK4,CDK2,SFN,PERP,P53AIP1,FAS,CCNB1,SERPINB5,CASP8,
CCNB2,EI24,CCND2,TP53I3,CCNE2,RFWD2,CCNB3,MDM2
HSA03050_Proteasome PSMB4,PSMA3,PSMA4,PSMA1,PSMB7,PSMD11,PSMD13,PSMD1,PSMC3,PSMA2,PSMA5,PSMD2,PSMA7,
PSMA6
Upregulated in LOH cases
HSA04370_VEGF_signaling_pathway MAPKAPK2,PLA2G10,PXN,PLA2G6,PLA2G2F,MAP2K1,MAP2K2,RAF1,PRKCG,PIK3R1,PLA2G1B,MAPK3,
MAPK12,SPHK2,AKT3,PLA2G2A,BAD,RAC1,PLA2G5,PIK3CD,NFATC3,PRKCA,PIK3CG
HSA05218_Melanoma FGF9,CCND1,MET,FGF17,FGF22,MAP2K1,MAP2K2,IGF1,RAF1,PIK3R1,MAPK3,CDK6,AKT3,FGF8,BAD,
FGF23,ARAF,FGF12,FGFR1,PIK3CD,PDGFRA,PDGFD,FGF7,PIK3CG
HSA04012_ERBB_signaling_pathway CAMK2G,SHC4,MAP2K1,MAP2K2,RAF1,STAT5B,PRKCG,PAK2,NRG3,RPS6KB2,CAMK2B,PIK3R1,PAK4,
NRG1,MAPK3,ERBB2,AKT3,TGFA,BAD,ARAF,CBL,ERBB3,PIK3CD,PRKCA,PIK3CG, PAK3
HSA04020_Calcium_ signaling_pathway GNA11,HTR4,CCKBR,CHP,ADRA1D,ITPR1,RYR2,SLC25A5,PHKA1,NOS1,PHKA2,SLC8A2,CACNA1C,ATP2B1,
MYLK,AGTR1,CAMK2G,CHRNA7,CAMK4,MYLK2,PRKCG,CAMK2B,GRM5,BDKRB1,ADCY8,RYR1,ERBB2,
SPHK2,TRHR,CALM3,PRKACG,ADORA2A,PLN,GNA14,TBXA2R,PTAFR,ERBB3,ADCY9,P2RXL1,TACR2,
CACNA1D,PDGFRA,HRH1,NTSR1,PLCB4,HTR2B,PRKCA, CACNA1I,SLC25A6,PTGER3,ITPKB
HSA04664_FC_epsilon_RI_ signaling_pathway PLA2G2F,VAV3,MAP2K1,MAP2K2,RAF1,PIK3R1,PLA2G1B,MAPK3,MAPK12,AKT3,PLA2G2A,RAC1,IL4,
PLA2G5,PIK3CD,IL5, PDK1,PRKCA,PIK3CG
HSA04010_MAPK_signaling_pathway DUSP8,MAP2K7,FGF21,CACNA2D3,MEF2C,FGF5,RPS6KA3,CACNA2D1,TGFBR2,TAOK2,CACNA2D2,
RAC3,NFKB2,CHP,FLNA,SRF,FGF9,DAXX,RPS6KA6,RRAS,MAPKAPK2,PLA2G10,NTRK1,CACNA1C,PLA2G6,
FGF17,FGF22,RAP1A,FLNC,MAP3K14,PLA2G2F,CACNB4,MAP2K1,GADD45A,RPS6KA1,NF1,MAP2K2,
RPS6KA5,RAF1,PRKCG,PAK2,TAOK3,MOS,MAPK8IP3,PLA2G1B, MAPK3,MAPK12,RRAS2,PRKACG,GADD45G,
AKT3,NTF5,FGF8, PLA2G2A,FLNB,RAC1,FGF23,FGF12,RASGRF2,FGFR1,PLA2G5,MAP3K8NLK PTPN5
CACNA1D IL1R1 PDGFRA ARRB2 MAP3K10 RPS6KA4 PPP5C FGF7 GNA12 CACNG5 MAP3K13
DUSP7 PRKCA MAP2K5 CACNA1I MAPK8IP2
HSA04150_MTOR_signaling_pathway VEGFB,RICTOR,PGF,AKT1,PRKAA1,RPS6KA3,RPS6KA6,RPS6KA1,IGF1,RPS6KB2,PIK3R1,EIF4B,MAPK3,
VEGFC,AKT3,FIGF, PIK3CD,PIK3CG
HSA05221_Acute_myeloid_ leukemia PIM2,NFKB2,STAT3,CCND1,FLT3,MAP2K1,CEBPA,MAP2K2,RAF1,RPS6KB2,JUP,MAPK3,TCF7,AKT3,
BAD,ARAF,PIK3CD, PIK3CG,KIT
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http://www.biomedcentral.com/1471-2164/15/390associated as a mechanism to evade the immune sur-
veillance in DLBCL and other types of cancer [30,31].
In addition, this finding also indicates that lymphoma-
genesis could be orchestrated by a network of TSGs that
are inactivated in malignant B-cells to block tumourFigure 4 Identification of genes located within the common LOH reg
of PTPRJ. A) Comparison of the differentially expressed genes between NH
within the common LOH regions in NHL cases (blue circle) discovered tha
B) is upregulated in cases with LOH of PTPRJ. NFATC3 mean fluorescence
Expression Beadchip [7].suppressor signalling and constitutively maintain patho-
genic signals.
PTPN11, highly targeted by LOH events in NHL, was
also identified in the PTPRJ interactome. PTPN11 en-
codes a protein tyrosine phosphatase (PTP) with two SH2ions in NHL cases whose expression is affected by the LOH status
L cases with retention and LOH of PTPRJ (red circle) and genes located
t NFATC3 gene in addition to being inactivated in NHL subtypes,
intensity values were obtained from an Illumina Sentrix Human-6 (v2.0)
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http://www.biomedcentral.com/1471-2164/15/390domains which acts as an intracellular signalling trans-
ducer of growth factors and cytokines receptors by regula-
tion of the MAPK pathway [32]. Furthermore, it has
been demonstrated that this PTP plays a crucial role
in hematopoiesis and that mutations in PTPN11 block
the T-cell and B-cell development [33]. Mutations in the
PTPN11 gene have been detected in low frequencies in
leukemia cases; however, alterations in this gene pre-
dispose patients with Noolan syndrome to several types
of leukemia (mainly juvenile myelomonocytic leukemia
JMML) and other types of cancer. [34-36]. Interestingly,
PTPN11 and PTPRJ share around 24 gene interactions,
which enriched important pathways in cancer such as
ERBB signalling pathway, cytokine-cytokine interactions
pathway, JAK/STAT signalling pathway and others. Thus,
this finding indicates that the inactivation of these two
PTPs may be a key factor in the malignant B-cell develop-
ment of these NHL subtypes, as double inactivation of
PTPRJ and PTPN11 may induce a constitutive activation
of oncogenic pathways regulated by these PTPs.
Additionally, the gene NFATC3 was identified as being
significantly upregulated in NHL cases with LOH of
PTPRJ. Interestingly, LOH of NFATC3 was identified to
be very common across FL and DLBCL cases and copy-
neutral events were found to be the driving cause of
LOH of NFATC3 in these cases, based on the previously
described high resolution LOH approach in these NHL
cases [8]. NFATC3 is a Ca++ -dependent protein that regu-
lates T-cell activation and migration, proliferation and
angiogenesis by regulation of VEGF [37]. Moreover, the
abrogation of NFATC3 expression in a murine model sug-
gested the implication of this TSG in T-cell lymphoma-
genesis; whereas, its implication in B-cell lymphomas has
not been studied [38]. In addition, NFATC3 was hypothe-
sized as being part of a mechanism whereby intratumoural
CD4+CD25+ T-cells (Treg cells) interact with activated
CD4+ T-cells to suppress the anti-tumour activity of infil-
trated CD4+ T-cells in B-cell NHL tumours and thus,
induce immune tolerance to these tumours [39]. Interest-
ingly, these Treg cells also suppress the cytotoxic activity
of CD8+ T-cells [40]. These findings suggest that B-cell
tumours may escape the immune surveillance through in-
activation of B2M, the malignant B-cell-mediated recruit-
ment of Treg cells and regulation of infiltrating CD4+,
possibly through NFATC3, and CD8+ T-cells. Further
studies are required to determine the role of NFATC3 and
its inactivation in B-cell lymphomagenesis, the copy-
neutral events driving LOH of NFATC3 and its relation
with the inactivation of PTPRJ, which is known to inhibit
the TCR-mediated T-cell activation by dephosphorylation
of LAT and PLCG1 pathways [14,41].
Although gene expression data was used to infer path-
ways of a protein tyrosine phosphatase, which lacks a DNA-
binding regulatory motif, we were able to identify genes withdifferent patterns of expression between cases with reten-
tion and LOH of PTPRJ, which suggests that the inactiva-
tion of PTPRJ might affect pathways whose ultimate goals
are to switch on/off transcription factors and as a result of
this, to induce an aberrant expression of these genes. In
addition, using a Gene Set Enrichment Analysis (GSEA)
of the differentially expressed genes between cases with
LOH and retention; several pathways related to cancer
and lymphocyte function were identified to be significantly
upregulated in cases with LOH. This upregulation may be
due to an indirect effect of the LOH of PTPRJ, which may
cause a constitutive activation of pathways and may result
in an abnormal expression of genes downstream of these
pathways. Nonetheless, further functional studies (i.e., im-
munoblot) are required to validate these results and con-
firm the effect of LOH of PTPRJ in the expression of these
oncogenic pathways.
For instance, the VEGF signalling pathway was found
as the most significant upregulated pathway in cases with
LOH of PTPRJ. This finding was expected as PTPRJ de-
phosphorylates VEGFR-2 and inhibits the VEGF-mediated
cell proliferation, migration, angiogenesis and anti-apoptosis
signalling [16]. Malignant activation of the VEGF signal-
ling pathway has been widely implicated in the tumour
growth and lymphangiogenesis of NHLs and the expres-
sion of VEGF has been considered as a poor prognostic
factor in these hematological malignancies and has been
implicated in transformation of FL to DLBCL [42-44].
Furthermore, the ERBB and MAPK signalling pathway
were also found to be upregulated in cases with LOH.
These oncogenic pathways have been previously described
to be dephosphorylated by PTPRJ [17,45,46]. Likewise, as
PTPRJ also affects changes in Ca++ concentration [19,47],
it was expected that inactivation of PTPRJ upregulates
Ca++ signalling pathways. Unexpectedly, signalling medi-
ated by the Fc epsilon receptor I was found to be also up-
regulated in LOH cases; however, despite that this receptor
for IgE is expressed in early stages of B-cells [48], its rela-
tion with PTPRJ is unclear.
On the other hand, the most enriched pathways in cases
with retention of PTPRJ were DNA polymerase, TP53
signaling and proteasome pathways. It is likely that the
upregulation of these pathways in cells with functional
PTPRJ are the consequence of the activation of tumour
suppressor activities, such as controlling cell proliferation
and proapoptotic signalling through dephosphorylation of
VEGFR, MAPK and PI3K pathways [16-18]. The upregu-
lation of proteasome pathway in cases with retention of
PTPRJ correlates with a previous study, which found that
a rat homolog of PTPRJ controlled the proteasome-
mediated degradation rate of its regulator (p27Ki) by acti-
vation of MAPK pathway [49]. Furthermore, an analysis
using freely available gene expression profiling data from
FL and DLBCL cases expressing high and low levels of
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http://www.biomedcentral.com/1471-2164/15/390PTPRJ [50,51], determined a low correlation of genes af-
fected by PTPRJ transcript abundance between FL and
DLBCL cases. This discrepancy may indicate differences
in the LOH-driving events targeting this TSG in FLs
and DLBCLs, which is supported by the significant
downregulation of PTPRJ in FL cases, but not in DLBCL
with LOH [8].
Conclusion
In conclusion, the use of pathway analytical approaches
has provided more evidence supporting the presence of
common pathogenic mechanisms underlying the lympho-
magenesis of FL and DLBCL. Specifically, this work iden-
tified genes and pathways affected by LOH of PTPRJ.
Furthermore, these findings suggest that PTPRJ plays a
crucial role in the lymphomagenesis of FL and DLBCL as
this TSG was found to induce aberrant expression of
genes and PTPRJ-regulated pathways in NHL cases with
LOH. Finally, it is important to highlight that the role of
the most promising TSGs and pathways affected by LOH
in FL and DLBCL tumourigenesis will need to be vali-
dated in further in vitro modeling experiments.
Methods
LOH pathway analyses
A total of 42 NHL cases, 21 DLBCL and 21 FL, were ana-
lysed using a high resolution LOH approach, which identi-
fied 46 common LOH regions across FL and DLBCL
cases, harbouring 262 candidate tumour suppressor genes
[8]. The global interactome of genes affected by LOH
events in NHL cases was built inserting these 262 candi-
date TSGs in the VisANT v. 4.06 (Integrative Visual
Analysis Tool for Biological Networks and Pathways) plat-
form to determine the level interaction amongst them.
Genes without any interaction were eliminated from the
analysis. In addition, a gene set enrichment analysis (GSEA)
was performed on these 262 candidate TSGs, in order to
investigate candidate TSGs with collections of curated
gene sets, such as canonical pathways, Biocarta, KEGG,
and Reactome, using the molecular signature database
(MsigDB, v3.1). The significance level for this GSEA ana-
lysis was set at α < 0.05. Both analyses were based on the
assumption that all the genes located within the inferred
LOH regions, previously described [8], were being tar-
geted by LOH events in the cohort of NHL cases.
Interactome of PTPRJ
In order to extend on recently published findings impli-
cating PTPRJ as a novel TSG in the lymphomagenesis of
FL and DLBCL [8] and to understand the unclear role of
PTPRJ in B-cell tumourigenesis, we used bioinformatics
tools to investigate the effect of LOH of PTPRJ on
genes and pathways. Thus, to identify candidate TSGs
affected by LOH events that interact directly or indirectlywith PTPRJ and play a role together with PTPRJ, within
common cellular networks, we extracted and analyzed
the interactome of PTPRJ from the global interactome
enriched with the 262 candidate TSGs [8], using the
VisANT v. 4.06 platform (Integrative Visual Analysis Tool
for Biological Networks and Pathways). In addition, the in-
teractome of PTPRJ was enriched with log2-transformed
data from an Illumina Sentrix Human-6 (v2.0) Expression
Beadchip from NHL cases (19 FLs and 20 DLBCLs) with a
known LOH status (15 RET and 14 LOH) [7,8].
Selection of differentially expressed genes
To determine differentially expressed genes between cases
with retention and LOH of PTPRJ, we used our previously
described linear gene expression profiling (GEP) data from
cases (19 FLs and 20 DLBCLs) with a known LOH status
(15 RET and 14 LOH) [7,8]. The ComparativeMarker
Selection module of the Genepattern platform [52] was
employed for this selection and the analysis was carried
out using the default options (2-sided T-Test and 10000
permutations). Results from this analysis were visualized
using the ComparativeMarkerSelectionViewer module. A
total of 400 (200 per status) differentially expressed genes
were selected by the ExtractorComparativeMarkerResults
module based on their score. Expression patterns were
visualized using the HeatMapViewer module. A Venn dia-
gram was used to identify common genes found to be dif-
ferentially expressed from the comparison of cases with
RET and LOH of PTPRJ and the 262 candidate TSGs iden-
tified within common LOH regions in NHL cases [8].
Comparison of the expression levels of NFATC3 (nuclear
factor of activated T-cells, cytoplasmic 3) between cases
with retention and LOH of PTPRJ was carried out using
an independent t-test (α < 0.05).
Gene set enrichment analysis (GSEA)
The identification of gene sets that were upregulated in
cases with RET and LOH of PTPRJ was performed using
the above mentioned GEP data from NHL cases with a
known LOH status (15 RET and 14 LOH) for PTPRJ in
the GSEA v 2.0 software. The collection of curated path-
ways from the KEGG database and the default settings
(without collapsing GEP data) were used for this ana-
lysis. Significance level was set at an α < 0.05.
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